February 13, 2008
NJ Pharma Co. To Pay Mass. $323,000
By Cory Hopkins
New Jersey pharmaceutical company Aventis Pharmaceuticals Inc. has agreed to pay the state and the Massachusetts Medicaid Program more than $323,000 to resolve claims of improper price reporting and marketing practices, according to state Attorney General Martha Coakley .
The payment to Massachusetts is part of a national settlement involving 38 states that has netted a refund of $22.7 million to state and federal medicaid programs, Coakley's office said.
The national investigation centered around Aventis' inflated and fraudulent Medicaid reimbursement levels for its prescription oncology medication Anzemet. In addition to the cash refund, Aventis has also agreed to the terms of a Corporate Integrity Agreement, which will subject the company to strict scrutiny of its marketing practices.
The payment to Massachusetts is part of a national settlement involving 38 states that has netted a refund of $22.7 million to state and federal medicaid programs, Coakley's office said.
The national investigation centered around Aventis' inflated and fraudulent Medicaid reimbursement levels for its prescription oncology medication Anzemet. In addition to the cash refund, Aventis has also agreed to the terms of a Corporate Integrity Agreement, which will subject the company to strict scrutiny of its marketing practices.
WBJ Web Partners
Most Recent
Most Recent
0 Comments